Skip to content

Released Nov 12, 2026, after the close

10-Q filed Nov 12, 2026, 43 days after period end · 0001708599-26-000068

Q3 2026 · 10-Q
Revenue$125.00K— vs Q3 2025no prior Q2 2026 on file
Net Income-$7.91MN/M vs Q3 2025N/M vs Q2 2026
EPS Diluted-$0.31N/M vs Q3 2025N/M vs Q2 2026
Operating Income-$7,861,000N/M
Operating Cash Flowderived-$5,495,000N/M
Free Cash Flowderived-$5,498,000N/M
Margins · derived
Operating margin-6288.8%
Net margin-6324.8%

What the release said

Serina Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Updates

Serina Therapeutics reported third quarter 2026 results, with operating expenses of $8.0 million and a net loss attributable to common stockholders of $7.9 million, or $(0.31) per basic and diluted share.123

In September 2026, the independent Safety Monitoring Committee recommended advancement of SER-252 to Cohort 2 of the registrational study, and dosing in Cohort 2 has been initiated.45

Topline data from the single-ascending-dose portion of the SER-252 study are expected in the first half of 2027.4

Cash and cash equivalents totaled $19.4 million as of September 30, 2026.6

Operating expenses, three months ended September 30, 2026
$8.0 million Compared with $6.4 million for the three months ended September 30, 20252
Net loss attributable to common stockholders, three months ended September 30, 2026
$7.9 million Compared with net loss of $4.7 million for 20253
Net loss per basic and diluted share, three months ended September 30, 2026
$(0.31) Compared with $(0.45) per share for 20253
Cash and cash equivalents as of September 30, 2026
$19.4 million Liquidity as of the quarter end6
Thaler Agent · checked against the filing
Open the reading ›
The release

Same quarter

MetricQ3 2026Q3 2025Q3 2024Q3 2023
Revenue$125.00K$0.00$14.00K$29.00K
Net Income-$7.91M-$4.59M$1.41M$1.75M
EPS Diluted-$0.31-$0.45$0.13$0.23

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Serina Therapeutics, Inc. · CIK 1708599 · Engraved from SEC EDGAR